Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Aptose Biosciences ( (TSE:APS) ) is now available.
Aptose Biosciences announced that the Nasdaq Hearings Panel has granted an extension for the company to meet the compliance criteria necessary for continued listing on the Nasdaq Stock Market. This decision allows Aptose until March 31, 2025, to adhere to Nasdaq Listing Rule 5550(b)(1) regarding shareholder equity and Rule 5550(a)(2) concerning minimum bid price requirements. The company has taken significant steps, such as securing an $8 million public offering and entering a clinical development agreement with the National Cancer Institute, to support the development of its lead drug, tuspetinib, for acute myeloid leukemia and myelodysplastic syndromes.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, specifically targeting hematologic malignancies. The company is dedicated to creating small molecule cancer therapeutics that offer efficacy both as single agents and in combination with other treatments, minimizing overlapping toxicities. Their primary drug candidate, tuspetinib, is designed for use in acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy for newly diagnosed AML patients.
YTD Price Performance: -92.99%
Average Trading Volume: 498,032
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $10.93M
See more data about APS stock on TipRanks’ Stock Analysis page.
